Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alicia Tosoni

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
Future Oncology (London, England)|July 25, 2019
Concordance between RTOG and EORTC prognostic criteria in low-grade gliomasEnrico Franceschi, Antonella Mura, Giuseppe Lamberti, et al.
Pathology, Research and Practice|April 22, 2021
The clinical and prognostic role of ALK in glioblastomaEnrico Franceschi, Dario De Biase, Vincenzo Di Nunno, et al.
Clinical Drug Investigation|August 17, 2021
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni, et al.
Diagnostics (Basel, Switzerland)|March 6, 2021
IDH1 Non-Canonical Mutations and Survival in Patients with GliomaEnrico Franceschi, Dario De Biase, Vincenzo Di Nunno, et al.
Cancers|June 13, 2025
Risk Factors for Malignant Transformation in Inverted Sinonasal Papilloma: A Systematic Review and Meta-AnalysisAndrea Ambrosini-Spaltro, Giulia Querzoli, Anna Caterina Leucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-OncologiaAlba A Brandes, Umberto Basso, Michele Reni, et al.
Pathology, Research and Practice|April 22, 2021
IDH1<sup>105GGT</sup> single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomasEnrico Franceschi, Dario De Biase, Vincenzo Di Nunno, et al.
Tumori|May 18, 2021
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective studyEnrico Franceschi, Santino Minichillo, Alicia Tosoni, et al.
Blood|March 6, 2004
Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomasLivio Trentin, Anna Cabrelle, Monica Facco, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 30, 2026
Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughsLidia Gatto, Riccardo Mei, Martina Stasolla, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Future Oncology (London, England)|July 25, 2019
Concordance between RTOG and EORTC prognostic criteria in low-grade gliomasEnrico Franceschi, Antonella Mura, Giuseppe Lamberti, et al.
Pathology, Research and Practice|April 22, 2021
The clinical and prognostic role of ALK in glioblastomaEnrico Franceschi, Dario De Biase, Vincenzo Di Nunno, et al.
Clinical Drug Investigation|August 17, 2021
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni, et al.
Diagnostics (Basel, Switzerland)|March 6, 2021
IDH1 Non-Canonical Mutations and Survival in Patients with GliomaEnrico Franceschi, Dario De Biase, Vincenzo Di Nunno, et al.
Cancers|June 13, 2025
Risk Factors for Malignant Transformation in Inverted Sinonasal Papilloma: A Systematic Review and Meta-AnalysisAndrea Ambrosini-Spaltro, Giulia Querzoli, Anna Caterina Leucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-OncologiaAlba A Brandes, Umberto Basso, Michele Reni, et al.
Pathology, Research and Practice|April 22, 2021
IDH1<sup>105GGT</sup> single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomasEnrico Franceschi, Dario De Biase, Vincenzo Di Nunno, et al.
Tumori|May 18, 2021
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective studyEnrico Franceschi, Santino Minichillo, Alicia Tosoni, et al.
Blood|March 6, 2004
Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomasLivio Trentin, Anna Cabrelle, Monica Facco, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 30, 2026
Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughsLidia Gatto, Riccardo Mei, Martina Stasolla, et al.
Pageof 11